High prevalence of resistance to first-line drugs and multidrug resistance in patients with tuberculosis and type 2 diabetes mellitus at a referral hospital in Peru
PLOS One · 20.08.2026 · 21 (8) · e0337152
DOI: 10.1371/journal.pone.0337152 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS One, online erschienen am 20.08.2026. Verfasst von Sergio Barboza-Panaifo und 4 weiteren Autor:innen. Beteiligte Einrichtung: Universidad Científica del Sur, Lima, Perú. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Tuberculosis, Multidrug-Resistant, Antitubercular Agents, Drug Resistance, Multiple, Bacterial. Die Arbeit nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Diabetes mellitus
Abstract (Originalsprache)
Introduction
The coexistence of tuberculosis (TB) and type 2 diabetes mellitus (T2DM) poses an emerging public health challenge, especially in high-TB-burden settings such as Peru. This comorbidity has been associated to unfavorable clinical outcomes and a higher frequency of drug-resistant TB.
Objective
To estimate the prevalence of resistance to first-line antituberculosis drugs and identify factors associated with multidrug resistance tuberculosis (MDR-TB) among patients with T2DM and pulmonary TB treated at a public hospital in Lima, Peru.
Methods
A cross-sectional study was conducted using secondary data from 130 adults with T2DM and microbiologically confirmed pulmonary TB treated at a Peruvian hospital between 2015 and 2019. Drug susceptibility results were categorized as susceptible, monoresistant, polyresistant, or MDR-TB. Factors associated with MDR and resistance to at least one first-line drug were evaluated using Poisson regression models with robust variance.
Results
The prevalence of resistance to at least one first-line drug was 34.6%, and the prevalence of MDR-TB was 21.5%. The most frequent resistances were to isoniazid (28.4%) and rifampicin (26.2%). In the multivariable analysis, age 40–49 years (aPR = 2.99; 95% CI: 1.00–8.97) and age 70–85 years (aPR = 4.13; 95% CI: 1.16–14.7) and were independently associated with MDR-TB. Furthermore, a diabetes duration of at least 5 years was associated with resistance to at least one drug (aPR ≈ 2.1).
Conclusion
A high prevalence of drug resistance, including MDR-TB was observed among patients with T2DM and pulmonary TB. Older age and longer duration of diabetes were associated with bacterial resistance in the adjusted analysis. These findings underscore the importance of considering diabetes-related clinical characteristics when evaluating drug resistance patterns in patients with tuberculosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Universidad Científica del Sur, Lima, Perú.
- Grupo de Investigación NEMECS: Neurociencias, Metabolismo, Efectividad Clínica y Sanitaria, Universidad Científica del Sur, Lima, Perú.
ORCID-Profile: Marlon Yovera-Aldana
Zitieren
APA
Barboza-Panaifo, S., Erazo-Cárdenas, I., Chapoñan-Agip, N. V., Tenorio-Quispe, A., & Yovera-Aldana, M. (2026). High prevalence of resistance to first-line drugs and multidrug resistance in patients with tuberculosis and type 2 diabetes mellitus at a referral hospital in Peru. PLOS One, 21(8), e0337152. https://doi.org/10.1371/journal.pone.0337152
Vancouver
Barboza-Panaifo S, Erazo-Cárdenas I, Chapoñan-Agip NV, Tenorio-Quispe A, Yovera-Aldana M. High prevalence of resistance to first-line drugs and multidrug resistance in patients with tuberculosis and type 2 diabetes mellitus at a referral hospital in Peru. PLOS One. 2026;21(8):e0337152. doi:10.1371/journal.pone.0337152
BibTeX
@article{BarbozaPanaifo2026,
author = {Barboza-Panaifo, Sergio and Erazo-Cárdenas, Italo and Chapoñan-Agip, Nallely V and Tenorio-Quispe, Anabell and Yovera-Aldana, Marlon},
title = {High prevalence of resistance to first-line drugs and multidrug resistance in patients with tuberculosis and type 2 diabetes mellitus at a referral hospital in Peru},
journal = {PLOS One},
year = {2026},
volume = {21},
number = {8},
pages = {e0337152},
doi = {10.1371/journal.pone.0337152}
}
EUVIMED